Circadian receives IND approval from FDA to initiate clinical trial of OPT-302 for wet AMD patients
15-Jun-2015 -
Circadian Technologies Limited through its wholly owned subsidiary Opthea Pty Ltd announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate its Phase 1 clinical trial of OPT-302 in patients with wet age-related macular ...
Investigational New Drug application
optical coherence tomograph
phase I studies
+1